Table 2. . Baseline demographic and clinical characteristics for patients with glioblastoma multiforme by MGMT promoter methylation status.
| Variable | MGMT methylation status† | |||
|---|---|---|---|---|
| Overall | Methylated | Unmethylated | p-value | |
| Total patient count (n) | 489 | 229 | 260 | |
| Age at diagnosis (years) | 0.9180 | |||
| Patients with available data (n) | 489 | 229 | 260 | |
| Mean, years (SD) | 61.5 (12.6) | 61.5 (13.0) | 61.4 (12.2) | |
| Median, years (min, max) | 62.8 (20.1, 89.6) | 62.1 (26.7, 89.6) | 63.1 (20.1, 85.9) | |
| Age group, n (%) | 0.9547 | |||
| <65 years | 282 (57.7) | 132 (57.6) | 150 (57.7) | |
| ≥65–75 years | 143 (29.2) | 66 (28.8) | 77 (29.6) | |
| >75 years | 64 (13.1) | 31 (13.5) | 33 (12.7) | |
| Sex, n (%) | 0.0343 | |||
| Female | 206 (42.1) | 108 (47.2) | 98 (37.7) | |
| Male | 283 (57.9) | 121 (52.8) | 162 (62.3) | |
| Race, n (%) | 0.0499 | |||
| Caucasian | 376 (76.9) | 176 (76.9) | 200 (76.9) | |
| Black or African–American | 11 (2.2) | 7 (3.1) | 4 (1.5) | |
| Asian | 10 (2.0) | 8 (3.5) | 2 (0.8) | |
| American–Indian or Alaskan native | 2 (0.4) | 2 (0.9) | 0 (0.0) | |
| Unknown | 90 (18.4) | 36 (15.7) | 54 (20.8) | |
| Ethnicity, n (%) | 0.7574 | |||
| Hispanic or Latino | 26 (5.3) | 11 (4.8) | 15 (5.8) | |
| Not Hispanic or Latino | 361 (73.8) | 164 (71.6) | 197 (75.8) | |
| Unknown | 102 (20.9) | 54 (23.6) | 48 (18.5) | |
| Practice region, n (%) | 0.9683 | |||
| South | 243 (49.7) | 112 (48.9) | 131 (50.4) | |
| West | 146 (29.9) | 68 (29.7) | 78 (30.0) | |
| Northeast | 71 (14.5) | 35 (15.3) | 36 (13.8) | |
| Midwest | 29 (5.9) | 14 (6.1) | 15 (5.8) | |
| ECOG PS at diagnosis, n (%) | 0.4814 | |||
| 0 | 30 (6.1) | 14 (6.1) | 16 (6.2) | |
| 1 | 261 (53.4) | 124 (54.1) | 137 (52.7) | |
| 2 | 75 (15.3) | 28 (12.2) | 47 (18.1) | |
| ≥3 | 15 (3.1) | 7 (3.1) | 8 (3.1) | |
| Unknown | 108 (22.1) | 56 (24.5) | 52 (20.0) | |
| Surgery type, n (%) | 0.9088 | |||
| Resection >90% | 10 (2.0) | 5 (2.2) | 5 (1.9) | |
| Resection <90% (not a biopsy) | 13 (2.7) | 5 (2.2) | 8 (3.1) | |
| Resection NOS | 405 (82.8) | 189 (82.5) | 216 (83.1) | |
| Biopsy | 61 (12.5) | 30 (13.1) | 31 (11.9) | |
| No GBM-related surgery | 428 (87.5) | 199 (86.9) | 229 (88.1) | 0.6942 |
| Resection v biopsy, n (%) | 254 (51.9) | 125 (54.6) | 129 (49.6) | 0.2380 |
| Steroid use prior to 1L treatment, n (%) | 489 | 229 | 260 | |
†
Patients with MGMT untested/indeterminate methylation status are not included.
Bold numbers are p-values indicating significant difference.
1L: First line; ECOG PS: Eastern Cooperative Oncology Group performance status; GBM: Glioblastoma; MGMT: O6-methylguanine-DNA methyltransferase; NOS: Not otherwise specified; SD: Standard deviation.